Working… Menu

Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab (MONITOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04605146
Recruitment Status : Recruiting
First Posted : October 27, 2020
Last Update Posted : July 27, 2021
Information provided by (Responsible Party):
Hospices Civils de Lyon

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 1, 2028
Estimated Study Completion Date : May 1, 2028